## DGX: Quest Diagnostics Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.47 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-8.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($174.89)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Octave Bio lands massive deal with Quest Diagnostics that will expand reach of its multiple sclerosis tests**
- Source: The Business Journals | 20251201T142052 | Bullish | Relevance: 99%
- Octave Bioscience has secured a significant deal with Quest Diagnostics, aiming to broaden the accessibility of its multiple sclerosis tests. This partnership is expected to advance precision medicine for MS and Parkinson's by focusing on the biological individualization of the disease. The CEO of Octave Bioscience, Doug Biehn, highlighted the importance of managing the disease based on its biology.

**2. First National Advisers LLC Purchases Shares of 8,980 Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251202T050820 | Somewhat-Bullish | Relevance: 99%
-  First National Advisers LLC initiated a new position in Quest Diagnostics (NYSE:DGX) during Q2, acquiring 8,980 shares valued at approximately $1.61 million. This comes amid significant insider selling from CEO J.E. Davis and SVP Mark E. Delaney, totaling over 94,000 shares. Quest Diagnostics reported strong Q3 earnings, beating estimates with $2.60 EPS and $2.82 billion in revenue, and declared a quarterly dividend of $0.80.

**3. Quest Diagnostics Inc. stock underperforms Monday when compared to competitors**
- Source: MarketWatch | 20251201T170500 | Neutral | Relevance: 99%
-  Quest Diagnostics Inc. (DGX) stock fell 2.86% to $183.77 on Monday, underperforming the broader market. This marked the stock's third consecutive day of losses, as the S&P 500 Index (SPX) declined 0.53% and the Dow Jones Industrial Average (DJIA) fell 0.90%.

**4. Quest Diagnostics, Octave Collaborate to Expand Multiple Sclerosis Disease Activity Test Access**
- Source: MarketScreener | 20251201T153300 | Somewhat-Bullish | Relevance: 98%
- Quest Diagnostics and Octave Bioscience have announced a collaboration to broaden access to Octave's Multiple Sclerosis Disease Activity Test across the United States. This partnership aims to make advanced diagnostic testing more widely available for individuals with multiple sclerosis.

**5. Quest Diagnostics (NYSE: DGX) to offer Octave MSDA MS blood test at 7,000 U.S. sites**
- Source: Stock Titan | 20251201T083000 | Bullish | Relevance: 98%
- Octave Bioscience has announced a strategic collaboration with Quest Diagnostics to expand access to the OctaveÂ® Multiple Sclerosis Disease Activity (MSDA) Test across the United States. This partnership will allow patients to access the blood test at approximately 7,000 Quest Diagnostics patient access sites nationwide, making it easier for physicians to order and utilize for informed treatment decisions for MS patients. The collaboration also establishes a pathway for future novel tests from Octave's precision neurology portfolio.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($1.18M) |
| Sells | 8 ($8.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.8% (+0.1%)
- Blackrock Inc.: 9.0% (-3.0%)
- JPMORGAN CHASE & CO: 7.8% (+99.3%)
- Price (T.Rowe) Assoc: 6.3% (-2.6%)
- State Street Corpora: 4.7% (+0.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-8.4% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $8.9M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.47 suggests fair value with growth premium. Forward P/E 17.6x stretched relative to 6% growth. Insider selling cluster ($8.9M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.1B |
| Beta | 0.62 |
| 52W Range | $148.70 - $197.55 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.47 |
| Forward P/E | 17.6 |
| Current P/E | 18.6 |
| YoY Growth | 5.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.0% to -3.3% (-8.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.3pp (needs >4.0% for momentum thesis). Underperforming sector by 3.1pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.03x) but short-term weakness (below SMA20). RSI neutral at 45.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.34% (CS: 22) | Weak |
| RSI_14 | 44.6 | Neutral |
| MACD Histogram | -0.37 | Bearish |
| vs SMA20 | 0.984x | Below |
| vs SMA50 | 0.992x | Below |
| vs SMA200 | 1.034x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $182.55
- **Stop Loss:** $174.89 (4.2% risk)
- **Target:** $197.87 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 130
- **Position Value:** $23,731.50
- **Portfolio %:** 23.73%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-01-27 (Est: $2.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.60 | +3.9% |
| 2025Q2 | $2.57 | $2.62 | +1.9% |
| 2025Q1 | $2.15 | $2.21 | +2.8% |
| 2024Q4 | $2.18 | $2.23 | +2.1% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*